New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:43 EDTOMEDOncoMed recent pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the recent pullback in shares of OncoMed following the FDA's partial clinical hold on vantictumab as a buying opportunity. Piper wants to own shares ahead of the company's data read-outs in the second half of 2014. It reiterates an Overweight rating on the stock with a $43 price target.
News For OMED From The Last 14 Days
Check below for free stories on OMED the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
16:21 EDTOMEDOn The Fly: Closing Wrap
Subscribe for More Information
10:17 EDTOMEDOncoMed hold being lifted an important achievement, says Piper Jaffray
Subscribe for More Information
08:33 EDTOMEDOncoMed announces removal of partial clinical hold by FDA for vantictumab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use